Erlotinib (Tarceva) ( DrugBank: Erlotinib )

1 disease

ID	Disease name (Link within this page)	Number of trials
94	Primary sclerosing cholangitis	1

94. Primary sclerosing cholangitis

Clinical trials : 142 / Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00955149 (ClinicalTrials.gov)	August 2009	5/8/2009	Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)	An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7	Primary Sclerosing Cholangitis;Trisomy 7;Cholangiocarcinoma;Chemoprevention	Drug: Erlotinib (Tarceva)	Mayo Clinic	Genentech, Inc.	Completed	18 Years	N/A	Both	6	Phase 1	United States

First Previous1Next Last